BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Synoptics Introduces a New Division, Synoptics Health


11/12/2012 1:24:19 PM

Cambridge, UK: Synoptics, a world leader in the development and manufacture of innovative digital imaging systems for scientific applications, is delighted to introduce its new Division, Synoptics Health (www.synopticshealth.com). This Division will focus on imaging techniques within the clinical environment.

Synoptics has been successfully developing and supplying imaging solutions to life science researchers across the globe since 1986. The new Synoptics Health Division is currently utilising that expertise to provide a patented fluorescence protein detection system, which has been developed over four years in partnership with Queen Mary University of London (QMUL).

The rationale for commercialising this protein detection technology is that the recent draft of the NHS CFPP-01-01 consultation document which offers guidance on decontamination of reusable surgical instruments states that fluorescence provides increased sensitivity and quantification of residual proteins on surgical instruments. Synoptics Health is therefore exploiting its technology in this field to meet the needs of this consultation document.

Paul Ellwood, CEO of Synoptics Health stated: “Comments in the CFPP-01-01 consultation document indicate that fluorescence is the most sensitive method for detection of proteins on surgical instruments. During the development of our prototype system and reagents in collaboration with QMUL, we have achieved a 100-fold increase in the sensitivity of protein detection over current methods and we are launching our first commercial fluorescence protein detection product at Medica.”

Ellwood continued: “We feel the time is right for us to forge better links with decontamination professionals, which is why we have opened our new division. Being able to talk to us at Synoptics Health will allow them to see how easily they could implement our simple technology into their facility, secure in the knowledge they will be guided every step of the way. Using ultra sensitive testing will ensure their decontamination processes are working efficiently and more importantly, will provide increased confidence that the surgical instruments they are sending out really are clean and safe.”

For Further Information Contact:

Jayne Arthur, Synoptics Health, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK.

Tel: +44(0) 1223-727114 Fax +44 (0) 1223-727101

Email: jayne.arthur@synopticshealth.com Web site: www.synopticshealth.com

About Synoptics Health

Synoptics Health, based in Cambridge, UK is a new division of Synoptics, a world-leader in the development and manufacture of innovative digital imaging systems for a range of life science applications. The Company has three other divisions, Syngene, Syncroscopy and Synbiosis of which Syngene is the largest.

Syngene produces advanced systems for molecular biologists to analyse and document fluorescent DNA on gels and has systems in all the major pharmas and academic institutes world-wide. Synoptics’ other divisions Syncroscopy and Synbiosis specialise in digital imaging solutions for microscopy and microbial applications respectively. The Company founded in 1986, currently employs 45 people, 20 of whom are based at Synoptics Inc. in the USA.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES